Skip to main content

Table 2 Tumor size changes in melanoma patients (Ipilimumab-refractory melanoma (KEYNOTE -002))

From: Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

 

Number of Prior Line of Therapy Received

1

2 +

(2L)

(3L+)

n

Median

Mean

Standard Deviation

n

Median

Mean

Standard Deviation

Pembrolizumab arm

 % of Early Tumor Size Changes (~Week 12)

78

−7.4

−10.0

31.3

200

−0.1

−2.4

43.1

 Best % of Tumor Size Changes

78

−11.2

−23.5

43.2

200

−9.4

−16.0

53.5